CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing) of paired diagnosis and relapse specimens from acute myeloid leukemia (AML) patients treated with venetoclax plus azacitidine

To understand relapse mechanisms related to AML patients treated with venetoclax plus azacitidine therapy, we performed CITE-seq on paired diagnosis and relapse specimens from an AML patient treated with the therapy. Overall design: An AML patient who achieved remission but ultimately relapsed from the venetoclax plus azacitidine therapy was chosen for this study. Cells were harvested from specimens at diagnosis and relapse stages of the patient's disease and subjected to CITE-seq analysis.